Divergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9983293
Abstract
Background: This study aims to evaluate the impact of adjuvant chemotherapy on cancer‐specific survival (CSS) and overall survival (OS) in patients with Stage IA ovarian clear cell carcinoma (OCCC) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We conducted a retrospective cohort study utilizing SEER data (2000–2021) to compare the prognosis of Stage IA OCCC patients who received adjuvant chemotherapy versus those who did not. Propensity score matching (PSM) was used to balance baseline characteristics between the groups. Competing risks regression and multivariate Cox regression analyses identified prognostic factors for CSS and OS. Results: A total of 1422 Stage IA OCCC patients were identified. After PSM, 776 patients (388 in each group) were included. For patients aged ≤ 50 years, chemotherapy was linked to worse CSS (89.5% vs. 96.2%, p = 0.007) and OS (89.3% vs. 95.9%, p = 0.008). Conversely, in patients aged > 70 years, chemotherapy was associated with improved CSS (93.0% vs. 81.9%, p = 0.038) and OS (86.0% vs. 72.4%, p = 0.006). These trends remained after PSM. Multivariate analysis showed that chemotherapy had little impact on OS and CSS. Subgroup analysis further indicated that chemotherapy negatively affected CSS and OS in patients aged ≤ 50 years. Conclusions: Adjuvant chemotherapy did not significantly improve survival outcomes in patients with Stage IA OCCC. However, its effects were age‐dependent, with older patients (> 70 years) experiencing improved survival, while younger patients (≤ 50 years) exhibited worse outcomes. These findings underscore the importance of individualized treatment strategies for Stage IA OCCC.Keywords
This publication has 27 references indexed in Scilit:
- Age-related genomic alterations and chemotherapy sensitivity in osteosarcoma: insights from cancer genome profiling analysesInternational Journal of Clinical Oncology, 2024
- Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinomaUltrasound in Obstetrics & Gynecology, 2018
- Ovarian carcinomas: at least five different diseases with distinct histological features and molecular geneticsHuman Pathology, 2018
- Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomesGynecologic Oncology, 2018
- Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinomaInternational Journal of Cancer, 2018
- Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?Gynecologic Oncology, 2017
- Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutionsGynecologic Oncology, 2016
- Ovarian clear cell carcinoma, outcomes by stage: The MSK experienceGynecologic Oncology, 2015
- Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancerGynecologic Oncology, 2015
- Clear cell carcinoma of the ovary: A review of the literatureGynecologic Oncology, 2012